Analytical comparison of in vitro-spiked human serum and plasma for PCR-based detection of Aspergillus fumigatus DNA: a study by the European Aspergillus PCR Initiative by Loeffler, Juergen et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/84234/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Loeffler, Juergen, Mengoli, Carlo, Springer, Jan, Bretagne, Stephane, Cuenca-Estrella, Manuel,
Klingspor, Lena, Lagrou, Katrien, Melchers, Willem J. G., Morton, C. Oliver, Barnes, Rosemary
Ann, Donnelly, J. Peter and White, P. Lewis 2015. Analytical comparison of in vitro-spiked human
serum and plasma for PCR-based detection of Aspergillus fumigatus DNA: a study by the European
Aspergillus PCR Initiative. Journal of Clinical Microbiology 53 (9) , pp. 2838-2845.
10.1128/JCM.00906-15 file 
Publishers page: http://dx.doi.org/10.1128/JCM.00906-15 <http://dx.doi.org/10.1128/JCM.00906-
15>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
1 
 
Analytical comparison of in vitro spiked human serum and plasma for the PCR-based 1 
detection of Aspergillus fumigatus DNA – a study by the European Aspergillus PCR 2 
Initiative 3 
 4 
Juergen Loefflera*, Carlo Mengolib, Jan Springera, Stephane Bretagnec, Manuel Cuenca 5 
Estrellad, Lena Klingspore, Katrien Lagrouf, Willem JG Melchersg, C. Oliver Mortonh, 6 
Rosemary A. Barnesi, J. Peter Donnellyg, and P. Lewis Whitej, on behalf of the European 7 
Aspergillus PCR Initiative 8 
   9 
Affiliations: aWuerzburg University, Wuerzburg, Germany, bUniversity of Padua, Padua, 10 
Italy, cParis Diderot University, Saint Louis Hospital-APHP, Paris, France; dSpanish National 11 
Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain; eKarolinska University 12 
Hospital, Stockholm, Sweden; fNational Reference Center for Mycosis, University Hospitals 13 
Leuven, Leuven, Belgium and Department of Microbiology and Immunology, KU Leuven, 14 
Leuven, Belgium;  gRadboud University Medical Centre, Nijmegen, The Netherlands, 15 
hUniversity of Western Sydney, Sydney, NSW, Australia; iCardiff University, UHW, Cardiff; 16 
jPublic Health Wales Microbiology Cardiff, UK.  17 
 18 
*Correspondence 19 
Prof. Dr. Jürgen Löffler 20 
University Hospital Wuerzburg 21 
Medical Hospital II, Building C11 22 
97080 Wuerzburg, Germany 23 
Telephone +49 931 20136412, Fax: +49 931 20136409 24 
Mailto: Loeffler_J@ukw.de 25 
JCM Accepted Manuscript Posted Online 17 June 2015
J. Clin. Microbiol. doi:10.1128/JCM.00906-15
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
2 
 
Abstract 26 
The use of serum or plasma for Aspergillus PCR testing facilitates automated and 27 
standardised technology. Recommendations for serum testing are available, and while serum 28 
and plasma are regularly considered inter-changeable for fungal diagnostics, differences in 29 
GM-ELISA performance have been reported and attributed to clot formation. Therefore it is 30 
important to assess plasma PCR testing to determine if previous recommendations for serum 31 
are applicable, and also compare analytical performance with serum PCR.  32 
Molecular methods testing serum and plasma were compared through multi-centre 33 
distribution of quality control panels, with additional studies to investigate the effect of clot 34 
formation and blood fractionation on DNA availability.  Analytical sensitivity and time to 35 
positivity (TTP) were compared and regression analysis performed to identify variables that 36 
enhanced plasma PCR performance. 37 
When testing plasma, sample volume, pre/post-extraction volume ratio, PCR reaction volume, 38 
duplicate testing and the use of an internal control PCR were positively associated with 39 
performance. When whole blood samples were spiked then fractionated, the analytical 40 
sensitivity and TTP were superior when testing plasma. Centrifugation had no effect on DNA 41 
availability, whereas the presence of clot material significantly lowered the concentration (p = 42 
0.028). 43 
Summary: Technically there are no major differences for molecular processing of serum and 44 
plasma, but the formation of clot material potentially reduces available DNA in serum. 45 
During disease Aspergillus DNA burdens in blood are often at the limits of PCR performance. 46 
Using plasma could improve performance while maintaining the methodological simplicity of 47 
serum testing.  48 
49 
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Introduction 50 
Invasive aspergillosis (IA) represents a serious health problem for the immunocompromised 51 
patient, especially those undergoing cancer chemotherapy, receiving corticosteroid therapy or 52 
immunosuppression to avoid allograft rejection or solid organ rejection. Aspergillus fumigatus 53 
is a ubiquitous mould, and the most frequent cause of Aspergillosis in humans causing a wide 54 
spectrum of diseases ranging from allergic to severe life-threatening invasive manifestations. 55 
Spores of A. fumigatus enter the body through inhalation and infection primarily occurs in the 56 
lungs. Accurate diagnosis of IA remains difficult. Given the limitations of clinical signs and 57 
the difficulty in obtaining appropriate specimens for diagnosis a significant proportion of 58 
cases remain undetected, resulting in late or inappropriate therapy, and increased mortality 59 
rates, that can be as high as 90% with cerebral disease (5). Hence, there is an urgent need for 60 
an accurate and standardized, diagnostic approach for IA.  61 
Performance of mycological diagnostics when testing serum or plasma samples is assumed to 62 
be similar. The revised EORTC-MSG definitions include galactomannan (GM) EIA for 63 
testing of both serum and plasma (3), although, the testing of plasma has not been validated 64 
by the manufacturer. A study comparing GM EIA performance in serum and plasma 65 
confirmed that the testing of plasma using the same thresholds was appropriate, but 66 
interestingly the mean index generated by testing plasma was significantly higher than that for 67 
serum [0.315 vs 0.279, P: 0.0398 (13)]. Moreover, four possible IA cases would have been 68 
classified as probable IA had plasma been tested. The authors hypothesised that differences in 69 
indices could be attributed to the formation of the blood clot potentially ensnaring some of the 70 
GM within the sample taken for serum testing. It is conceivable that the same might be true 71 
for extracellular DNA, the Aspergillus target in the cell free fraction of host blood, affecting 72 
PCR performance. 73 
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This manuscript describes further efforts of the European Aspergillus PCR Initiative 74 
(EAPCRI) to evaluate the analytical performance of plasma and serum samples through the 75 
blinded distribution of simulated panels, as described previously for whole blood and plasma 76 
(12, 15).  We report data on differences in analytical performances associated with the 77 
different sample types (plasma versus serum) and on how differences in the initial formation 78 
of the sample types (clot versus no clot) and sample processing (whole blood centrifugation) 79 
affected the availability of DNA within the cell free sample itself.  80 
As a companion to this analytical in vitro study, a further multi-centre clinical study, which 81 
compares performances of plasma and serum was performed in parallel (11). 82 
83 
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Material and Methods  84 
 85 
DNA source material 86 
DNA was obtained from a sporulating culture of Aspergillus fumigatus (ATCC strain 1022). 87 
Conidia were harvested and DNA was extracted as described before (15).  88 
 89 
Participants 90 
The participants comprised of 8 laboratories representing the EAPCRI core facilities and an 91 
extended group of a further 15 laboratories. To maintain impartiality throughout the analytical 92 
process, all centres were given a numerical code to allow blinded review of individual 93 
methodological procedures, determination of performance, and statistical analysis. 94 
 95 
Panels 96 
All EDTA whole blood and clotted blood samples were obtained from consenting healthy 97 
volunteers, and screened for the presence of infectious agents as per protocol of the Institute 98 
of Transfusion medicine, Wuerzburg University Hospital, (Wuerzburg, Germany) and 99 
approved by the local ethical review board. Serum and plasma were fractionated by 100 
centrifugation and pooled respectively, before being distributed to Public Health Wales, 101 
Microbiology Cardiff, to develop the panel. To avoid airborne contamination all processing of 102 
material took place in a category 2 laminar flow cabinet. The panel was validated through 103 
testing with an “in-house” Aspergillus specific real-time PCR (14). Panels were distributed by 104 
courier on dry ice. Participating centres were asked to confirm receipt, comment on the state 105 
of the panel (frozen or thawed) and keep specimens frozen at -80°C until testing.  106 
 107 
Analytical testing was performed by using a four part process, as follows: 108 
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i) Assessing the analytical performance of Aspergillus PCR methods when 109 
testing serum  110 
Initially, serum was divided into 3 x 35 ml aliquots; one aliquot was retained to provide a 111 
negative control sample, while two aliquots were spiked with 100 and 10 genome equivalents 112 
(ge) of A. fumigatus DNA per ml of serum, respectively. The 35 ml serum batches were 113 
further divided into 1ml aliquots and frozen at -80°C until distribution on dry ice to the 23 114 
centres. This panel was a quality control (QC) exercise designed to confirm the findings of the 115 
previous research investigating serum, in doing so providing a reference for comparison with 116 
the plasma results, but also determining centres with optimal results for the analyses of further 117 
panels, including the analysis of plasma samples (15).    118 
 119 
ii) Assessing the analytical performance of Aspergillus PCR methods when 120 
testing plasma 121 
Plasma was divided in 8 x 12 ml aliquots; two aliquots were retained to provide negative 122 
control samples, while six aliquots were spiked with varying concentrations of A. fumigatus 123 
genomic DNA (1000, 100, 50, 10, 5, 1 and 0 ge/ml) and divided into 1ml aliquots. Panels 124 
were distributed on dry ice to the 8 EAPCRI core centres for testing.  125 
In keeping with previous studies, the threshold of detection, based on 95% variance was set at 126 
10 ge/ml (15).  127 
 128 
iii) Assessing the DNA availability in serum/plasma – Whole blood spiking 129 
DNA was spiked into blood collected into an EDTA vacutainer and into a vacutainer without 130 
any anticoagulant, immediately after sampling, but before centrifugation. Blood was spiked 131 
with varying concentrations of genomic A. fumigatus DNA (100, 50, 10 and 0 ge/ml, Figure 132 
1). Both, EDTA and clotted blood vacutainers were left for a minimum of 30 mins at room 133 
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temperature to allow the blood without anticoagulants to clot. Vacutainers were then 134 
centrifuged (3500 g for 5 mins) to separate the cell free fractions, which were pooled 135 
according to sample type and initial concentration of fungal burden. Each sample was then 136 
divided into 0.5 ml aliquots (potential target burden range 50, 25 5 and 0 ge), frozen at -80°C 137 
prior to distribution on dry ice. Serum and plasma samples were shipped on dry ice to the 8 138 
EAPCRI core centres. 139 
 140 
iv) Investigating the effects of clot formation and blood fractionation on the 141 
availability of A. fumigatus genomic DNA 142 
The following experiments were performed in a two-centre study in Cardiff and Wuerzburg 143 
using the following identical spiking protocols, respectively. 144 
 145 
Impact of centrifugation  146 
Two 4 ml aliquots of serum and plasma were spiked with 100 genome equivalents of A. 147 
fumigatus DNA, respectively. An aliquot of plasma and an aliquot of serum were centrifuged 148 
at 3500 g for 5 mins, mimicking the centrifugation process necessary to fractionate blood 149 
samples and potentially identifying any losses associated with this process. The other aliquot 150 
of plasma and serum, equivalent to a direct spike control remained untouched at ambient 151 
temperature until further processing by extraction. DNA was extracted from a minimum of 152 
three replicates of 0.5 ml of serum and 0.5 ml plasma spiked but not centrifuged, and 153 
minimum of three replicates of 0.5 ml of serum and 0.5 ml plasma spiked and centrifuged. 154 
DNA was extracted using the in-house protocols of both centres (10, 16). Briefly, in Cardiff, 155 
Aspergillus DNA was extracted using the Qiagen EZ1 DSP virus kit as per manufacturer’s 156 
instructions, with DNA eluted in 60 µl, in Wuerzburg, the QIAamp UltraSens Virus kit 157 
(Qiagen) was used as described by the manufacturer and DNA was eluted in 70 µl. Both 158 
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protocols comply with the EAPCRI recommendations for testing serum (15). PCR was 159 
performed in duplicate and included an internal control to measure PCR inhibition.  160 
 161 
Impact of clot formation  162 
Immediately after blood was drawn, 4 ml of EDTA whole blood and 4 ml of clotted blood 163 
were spiked with 100 ge of A. fumigatus DNA. Clotted blood was left at ambient temperature 164 
for 30 mins to coagulate, while EDTA blood remained untouched at room temperature for the 165 
same period. Samples were then centrifuged at 3500 g for 5 mins. After centrifugation, a 166 
minimum of three 0.5 ml aliquots of plasma and serum, as well as the cell pellet from the 167 
EDTA whole blood samples were extracted using local protocols and DNA was eluted in 168 
<100 µl. The clot was not processed as no EAPCRI validated procedures are currently 169 
available. PCR was performed in both centres using in-house amplification protocols and an 170 
inhibition control, all in accordance with EAPCRI guidelines (15). 171 
 172 
Statistical analysis 173 
Centres were requested to return both qualitative (positive/negative) and quantitative 174 
(quantification cycle [Cq value]) results within a designated time frame and provide detailed 175 
protocols for their DNA extraction and PCR amplification systems. Information required 176 
included sample volume used, extraction method, DNA elution volume, PCR method, PCR 177 
target, PCR template input volume, PCR total reaction volume, PCR amplification platform 178 
and internal control PCR results. 179 
The correlation between Cq and genomic load was estimated by linear regression. The Cq 180 
was the dependent variable, whereas the explanatory variables were i) the genomic load (as 181 
log10 genomic DNA), ii) the spiked sample type (as a binary variable for serum or plasma), 182 
and iii) the interaction between genomic load and fluid. A multilevel mixed-effects model was 183 
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performed, using the centres as a grouping variable. This model was comparable to a 184 
simplified calibration curve, also comparing the calibration lines concerning serum and 185 
plasma. The model was graphically reported. 186 
In addition, bivariate linear regression was performed to analyze possible associations 187 
between PCR sensitivity and selected covariates (Table 1). 188 
189 
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Results 190 
i) Assessing the analytical performance of Aspergillus PCR methods when 191 
testing serum  192 
The serum analysis in this QC panel compared favourably with the previous EAPCRI serum 193 
evaluation (15). All the 23 centres were able to reproducibly detect the sample that was spiked 194 
with 100ge and generate negative results when testing the sample not containing Aspergillus-195 
DNA. Samples spiked with 10 ge / ml generated an overall positivity rate of 74% (17 / 23 196 
centres) and a positivity rate of 82% (14 / 17) in centres that strictly followed EAPCRI 197 
recommendations for serum. Five out of the 6 centres who did not follow EAPCRI 198 
recommendations were unable to detect 10 ge / ml. Centres that were unable to detect the 10 199 
ge / ml did not routinely process serum samples (6/6) or used serum volumes below 0.5 ml 200 
(5/6, range 0.1 – 0.2 ml serum). In addition, these centres used only a small portion of their 201 
original serum sample volume in the subsequent PCR assay (mean 7.9%, range 1% - 25%), 202 
compared to a mean volume of 24.4% (range 16% - 82%) for centres that were able to detect 203 
10 ge / ml (p = 0.028).  204 
 205 
ii) Assessing the analytical performance of Aspergillus PCR methods when testing 206 
plasma 207 
All centres that had received this plasma panel were requested to follow the EAPCRI 208 
guidelines for serum testing and their positivity rates in the related QC serum panel were 209 
100%, 100% and 0% (100, 10, 0 genome equivalents / ml, respectively).  210 
Table 2 summarizes the results of the 8 centres. No samples were found to be inhibitory to 211 
PCR amplification. All 8 centres achieved 100% positivity for fungal burdens between 5 212 
ge/ml and 1000 ge/ml, while the sample spiked with 1 ge/ml was positive in a single sample 213 
of one centre only (Figure 2). Six out of 8 centres stated that they use either serum or plasma 214 
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or both in their routine diagnostic procedures (2 centres mainly tested bronchoalveolar 215 
lavages).  216 
Centres used between 0.1 ml and 1 ml (mean 0.5 ml) of plasma for subsequent DNA 217 
extraction, 50 – 100 µl (mean 60 µl) of elution volume and 2 – 15 µl (mean 8.7 µl) of 218 
template volume for their PCR assays. In bivariate analyses, we observed significant positive 219 
correlations between PCR sensitivity and the volume of plasma used for DNA extraction, the 220 
ratio between the volume of plasma used for extraction and the subsequent elution volume, 221 
the reaction volume used for PCR, the analysis of ≥2 replicates and the use of an internal 222 
control (Table 1).  223 
To provide complete Cq values for a range of different plasma volumes, a linear mixed model 224 
was used, which predicts Cq values for hypothetical plasma volumes (0.1 ml – 0.5 ml) and 225 
various A. fumigatus DNA concentrations (5 – 1000 ge / ml). The model shows that both, 226 
plasma volume and DNA load influence Cq values (e. g. predicted Cq values for 5 ge / ml 227 
ranged depending on the plasma volume between 37.6 and 40.7 [Table 3]).  228 
 229 
iii) Assessing the DNA availability in serum/plasma – Whole blood spiking 230 
In order to measure the availability of DNA in the cell free fraction post whole blood 231 
processing, an additional panel, consisting of 4 serum samples and 4 plasma samples was 232 
shipped to the 8 core EAPCRI centres. Our linear model showed that while the slope for PCR 233 
from plasma and serum did not differ significantly (p = 0.381), the plasma intercept was 4.3 234 
cycles lower (standard error = 1.38, 95% confidence interval -6.996 / -1.585) than the serum 235 
intercept (z = -3.11, p = 0.002). Interestingly, this shift in Cq values was achieved at all DNA 236 
concentrations tested (50, 25, 5 ge / ml, Figure 3). No inhibition was observed. Centre-237 
specific methodological details are shown in Table 4. Individual performance of centres in 238 
this panel was significantly associated with the volume of sample used for DNA extraction. 239 
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While both centres using 0.2 ml of serum or plasma achieved suboptimal sensitivity not 240 
detecting the serum sample spiked with 5 ge / ml, centres using ≥0.5 ml of plasma and serum 241 
were able to detect this sample as positive (p<0.001 [Table 4]). In addition, we observed a 242 
trend that laboratories, which routinely test serum or plasma by Aspergillus PCR achieved 243 
higher sensitivity (p = 0.07).  244 
 245 
iv) Investigating the effects of clot formation and blood fractionation on the 246 
availability of A. fumigatus genomic DNA 247 
In order to identify any potential losses of DNA during centrifugation necessary to fractionate 248 
blood samples, the recovery of DNA from spiked serum and plasma specimens that were 249 
centrifuged at 3500 g were compared to spiked samples that were not centrifuged. In both 250 
centres, there were no significant differences in Cq values between centrifuged or non-251 
centrifuged samples, for either plasma or serum (Table 5). These results demonstrate that 252 
centrifugation at 3500 g is not sufficient to sediment free DNA from serum and plasma. 253 
Interestingly, in both centres, plasma, obtained after centrifugation of spiked EDTA blood 254 
samples, showed earlier Cq values, compared to serum obtained from the corresponding 255 
clotted blood samples (difference of the mean Cq values between plasma and serum Δ = 2.26, 256 
standard error = 0.45, p = 0.0002). The concentration of genomic DNA added to the PCR 257 
reaction was significantly lower (p = 0.028) in serum samples post clot formation (mean 1.9 258 
copies, SD: 0.8) compared to DNA extracted from serum not influenced by clot formation 259 
(4.2 copies, SD: 1.3). Although it is likely that a substantial amount of A. fumigatus DNA is 260 
bound, during blood clot formation, and consequently is unavailable for DNA extractions 261 
using serum, it was not possible to test the clot material as optimized protocols are not 262 
available, and technical limitations prevent the processing of the entire clot material, which in 263 
this scenario was > 2ml in volume. However, whole blood cell pellets from centrifuged 264 
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EDTA vacutainers, containing peripheral blood mononuclear cells were tested. Relatively 265 
small amounts of A. fumigatus DNA (Mean: 0.4 input copies) were detectable in samples at 266 
both centres (centre 1: 1/4 samples positive [Ct value= 51.9], centre 2: 2/5 samples positive 267 
[Ct values=40.2, 42]), although it appears that the majority of the DNA remains in the plasma 268 
fraction (Mean: 3.3 input copies). 269 
270 
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Discussion 271 
The European Aspergillus PCR Initiative (EAPCRI) has published standards for Aspergillus 272 
PCR and protocols for detecting Aspergillus DNA in whole blood (12) and serum (15). The 273 
identification of the critical stages of Aspergillus DNA extraction from both specimen types 274 
allowed the EAPCRI to propose a protocol that helps ensure optimal performance of 275 
Aspergillus PCR across laboratories. However, no such data exist for plasma and no direct 276 
comparison between plasma and serum specimens has been performed. Thus, EAPCRI 277 
continued its efforts to evaluate the analytical performance of plasma, compared with serum 278 
samples through the blinded distribution of simulated panels. In parallel, a multi-centre 279 
clinical study was performed to compare detection of A. fumigatus DNA isolated from plasma 280 
and serum obtained from haematological patients (11).  281 
Plasma specimens were spiked with genomic A. fumigatus DNA. The group of 8 EAPCRI 282 
core laboratories were able to demonstrate that Cq values obtained from plasma were 283 
significantly lower (p = 0.002, Figure 3) than Cq values from sera (50, 25, 5 genome 284 
equivalents). 285 
Almost 15 years ago, Loeffler et al. compared sensitivities of A. fumigatus DNA detection 286 
from plasma and whole blood (7). Although plasma and whole blood samples spiked with 287 
Aspergillus conidia showed an identical lower detection limit (10 CFU), the sensitivity of 288 
plasma PCR was inferior to that of PCR performed on whole blood samples obtained from 289 
patients with proven IA. However, both DNA extraction and PCR amplification technology 290 
has advanced over the past decade. In addition, the quality of molecular diagnostics has 291 
advanced through numerous External Quality Assessment initiatives, including the EAPCRI, 292 
the Minimum Information for Publication of Quantitative Real-Time PCR Experiments 293 
(MIQE) guidelines (2) and the Quality Control for Molecular Diagnostics (QCMD; 294 
http://www.qcmd.org). In a recent study comparing EAPCRI methods for the testing of serum 295 
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and whole blood there was a trend towards superior sensitivity when testing whole blood, but 296 
this did not reach statistical significance, and any benefit was outweighed by the simplicity of 297 
testing serum (10).  298 
The current study demonstrated that after spiking whole blood the PCR testing of plasma 299 
samples showed superior sensitivity to that of serum (p = 0.002, Figure 3). To our knowledge, 300 
no data comparing the detection of A. fumigatus DNA detection in both serum and plasma 301 
exists. Lau et al. showed that Candida DNA was detected more often in serum (71%) and 302 
plasma (75%) than in whole blood (54%) in a study of 109 patients with candidemia (6). 303 
However, there was no significant difference between plasma and serum, possibly because of 304 
the relatively small numbers of serum and plasma specimens that were tested (n=29; n=24), or 305 
the differences in fungal disease manifestation. With respect to IA, the concentration of 306 
galactomannan as determined by EIA was shown in another study to be significantly higher in 307 
plasma than in serum (P: 0.0398), and may have been associated with the formation of clot 308 
(13). 309 
The presence of compounds that may interfere with molecular assays is always a concern 310 
when processing clinical samples. Compared to serum, plasma samples contain various 311 
coagulation factors that lead to the conversion of fibrinogen to fibrin and clot formation. 312 
Fibrinogen is a soluble protein, which is exclusively found in plasma (normal range 150-400 313 
mg/dL), but not in serum and has been shown to interact with magnesium, which is also an 314 
essential component of the PCR reaction (9). If this interaction results in lowering the 315 
magnesium concentration, it could result in PCR failure. All DNA extraction protocols used 316 
by the 8 EAPCRI study centres (Table 4) provided plasma DNA eluates that yielded superior 317 
sensitivity and lower Cq values compared to serum indicating that the additional components 318 
in plasma had no effect on PCR efficiency. In addition, the source of anticoagulant is also 319 
important; Garcia et al. (4) showed in rat blood that when comparing sodium citrate, heparin 320 
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and tripotassium-EDTA as anticoagulants, only the latter did not interfere with PCR used to 321 
diagnose IA.    322 
The EAPCRI specific recommendations for Aspergillus PCR in serum included the use of a 323 
minimum volume of 0.5 ml serum as starting material, DNA elution in a volume <100 µl (p = 324 
0.003) and the use of an internal control (15). For plasma, bivariate linear regression was used 325 
to evaluate similar covariates, finding a statistically significant positive association between 326 
PCR sensitivity and larger sample volumes (≥0.5 ml plasma), the use of ≥2 replicates (from a 327 
single eluate) and an internal control. While the DNA elution volume itself is not significantly 328 
associated with PCR sensitivity, the ratio of the initial plasma sample volume to the 329 
subsequent elution volume was significantly associated (z = -2.32, p = 0.02, Table 1). All 8 330 
core centres complied with EAPCRI serum recommendations on elution volume (<100 µl 331 
(15)) so correlation with PCR sensitivity is only to be expected. However, the use of an 332 
internal control was correlated and found to be statistically significant. Although this 333 
parameter is only indirectly associated with the detection of A. fumigatus DNA, it reflects the 334 
degree of diligence and accuracy of an individual laboratory.   335 
Interestingly, A. fumigatus genomic DNA, spiked into EDTA whole blood and left untouched 336 
for 30 minutes was detectable in small amounts in some leukocyte pellets as well as the cell 337 
free fraction. This suggests that circulating extracellular DNA reaches the cell pellet, either by 338 
gravitational force or due to binding to leukocyte surface receptors. Indeed, Bennett et al.  339 
showed that there is a common binding site for DNA on white blood cells (1). However, when 340 
comparing this to the detection of A. fumigatus DNA in serum clots, only 3/9 leukocyte 341 
pellets showed weak PCR-positive results whereas McCulloch et al reported significantly 342 
more Aspergillus DNA detectable in serum clots compared to the cell-free fraction (p<0.001, 343 
95% CI 2.24 to 6.48 [8]). These authors found that the average Cq value for the clot sample 344 
was 2.38 cycles lower than for EDTA blood and 3.69 cycles lower than for serum. While this 345 
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equates to a 7.9- and 12-fold increase in DNA yield from the clot, respectively, difficulties in 346 
processing these samples limits their use in routine practice. This observation might partially 347 
explain our observation that Cq values from native serum (used before clotting) developed 348 
consistently later compared to Cq values obtained from native plasma samples, both spiked 349 
with identical number of genome equivalents. 350 
In conclusion, the analytical sensitivity of plasma, as determined by multi-centre evaluation of 351 
PCR-based detection of A. fumigatus DNA is superior compared to serum. Recommendations 352 
published by EAPCRI for serum (15), including sample volume, a minimum of duplicate 353 
PCR testing of each DNA extract and an internal control can be applied to plasma.  354 
To confirm the analytical findings described here, a parallel multi-centre clinical study was 355 
performed. The retrospective case-control study supports the findings of this analytical 356 
manuscript and comes to the conclusion that there is a trend towards increased sensitivity of 357 
plasma, although this did not reach significance (P = 0.0897), and positivity was most 358 
frequently earliest when testing plasma by PCR (11).  359 
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Figure 1: Flow diagram highlighting the process for determining the availability of 473 
Aspergillus DNA in serum and plasma samples post blood fractionation 474 
 475 
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Figure 2: Descriptive statistics for Aspergillus real-time PCR crossing points when testing 476 
plasma samples containing various concentrations of Aspergillus fumigatus genomic DNA. 477 
Means (solid dots), 95% confidence intervals of the means (vertical bars), and single 478 
observations (empty circles) are shown for each fungal load. 479 
 480 
 481 
  482 
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Figure 3: Comparison of Aspergillus real-time PCR when testing serum and plasma samples 483 
containing various fungal loads using a linear mixed model. Data are shown after the 484 
regression of the Cq value versus the fungal genomic burden, with serum or plasma as a 485 
binary covariate.  486 
 487 
 488 
  489 
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Figure 4a: Flow diagram highlighting the process for determining the effect of centrifugation 490 
on the availability of Aspergillus DNA in serum and plasma samples. 491 
 492 
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Figure 4b: Flow diagram highlighting the process for determining the effect of clot formation 494 
on the availability of Aspergillus DNA in serum compared to the processing of plasma 495 
samples. 496 
 497 
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anticoagulant, but prior to clot 
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Decant 3 replicates of 0.5ml 
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DNA extraction:
3x 0.5ml plasma
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Aspergillus PCR amplification 
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EAPCRI recommendations
Retain EDTA whole blood 
pellet
DNA extraction:
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Aspergillus PCR amplification 
in duplicate and IC PCR using 
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Table 1: Bivariate analysis for the sensitivity of Aspergillus PCR testing spiked plasma 498 
specimens distributed to 8 EAPCRI core centres. All continuous and binary center-specific 499 
covariates were included into the basic model. With a negative sign of the z-score, the 500 
variable tended to exert a favorable effect on the PCR assay. The covariates exerting a 501 
significant effect are indicated by a P < 0.05 (*) and an absolute z-score > 1.96 502 
 503 
Variable Z-Score P-Value 
No of plasma samples 
analyzed / month -1.61 0.107 
Plasma starting volume -2.50 0.01* 
DNA elution volume -0.65 0.513 
Ratio starting plasma 
volume : elution volume -2.32 0.02* 
Total PCR reaction 
volume -2.64 0.01* 
Template volume -1.47 0.141 
Use of internal control -4.90 0.00* 
Use of ≥2 replicates -2.31 0.02* 
Percentage of eluate 
volume used in PCR -0.95 0.343 
  504 
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Table 2: Aspergillus PCR performance using plasma samples spiked with different fungal 505 
loads 506 
 507 
Sample 
No 
Burden 
genomes/ml 
95% sample 
variance 
Positivity rate (% 
/95% CI) Mean Cq (95% CI) Std. Err. 
1 1000 939.6-1060.4 100 32.4 (30.7-34.0) 0.70 
2 100 80.8-119.2 100 36.1 (34.1-38.1) 0.84 
3 50 36.4-53.6 100 36.9 (35.1-38.7) 0.75 
4 10 4.0-16.0 100 39.00 (37.1-40.9) 0.79 
5 5 0.8-9.2 100 39.9 (37.8-42.0) 0.88 
6 1 0-2.92 8.3 40.0* n. a. 
7, 8 0 x2 n. a.  0 No signal n. a.  
 508 
*Plasma 6 was positive in one single centre in a single sample only  509 
Plasma samples 1 – 8 were spiked with different fungal burdens (genome equivalents [ge] / 510 
ml plasma); results shown as mean Cq values, standard errors (Std. Err.) and 95% Confidence 511 
intervals (Conf. Interval); n. a. = not available 512 
  513 
29 
 
Table 3: The influence of sample volume (0.1-0.5 ml) on Aspergillus real-time PCR crossing 514 
points when testing plasma samples containing a range of Aspergillus fumigatus genomic 515 
DNA concentrations (5-1000 ge/ml). Prediction of Cq values calculated using a linear mixed 516 
model. 517 
 518 
Plasma 
volume [ml] 
Fungal load [ge / ml plasma] 
5 10 50 100 1000 
0.1 40.68 39.70 37.43 36.45 33.21 
0.2 39.90 38.92 36.65 35.67 32.42 
0.3 39.11 38.14 35.86 34.89 31.64 
0.4 38.33 37.35 35.08 34.11 30.86 
0.5 37.55 36.57 34.30 33.32 30.07 
 519 
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Table 4: Details of the molecular procedures used by the EAPCRI centres investigating the performance of Aspergillus PCR when testing serum 520 
and plasma 521 
 522 
EAPCRI 
Centre # 
Monthly serum 
sample numbers 
DNA 
extraction 
volume 
[ml] 
DNA extraction 
system 
Elution 
volume 
[µl] 
Template 
volume [µl] 
PCR 
reaction 
volume 
[µl] 
PCR 
target 
gene 
Sensitivity 
Serum [%] 
Sensitivity 
Plasma [%] 
1 0 0.2 MagNAPure  50 10 20 18S 66.7 100 
2 80 1 QIAamp 
UltraSense Virus 
70 10 21 ITS 100 100 
3 40 1 QIAamp 
UltraSense Virus 
38 10 21 ITS 100 100 
4 15 0.2 QIAamp DNA 
Mini 
50 2 20 ITS 0 100 
2 
 
5 70 1 MagNAPure Total 
NA Large Volume 
50 10 20 18S 100 100 
6 240 0.5 EZ1 DSP Virus 60 15 50 28S 100 100 
7 
 
8 
50 
 
10 
0.5 
 
0.5 
MagNAPure Total 
NA Large Volume 
MagNAPure Viral 
NA Large Volume 
100 
 
50 
5 
 
10 
20 
 
50 
28S 
 
28S 
100 
 
100 
100 
 
100 
 523 
  524 
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Table 5: The effect of centrifugation at 3500 x g on DNA recovery (as indicated by mean Cq values) from spiked serum and plasma specimens. 525 
Both centres revealed no significant differences in Cq values between centrifuged and non-centrifuged plasma and serum samples, respectively, P > 526 
0.05 (*) 527 
 528 
Material 
Centre 1 
[Mean Cq values] 
Centre 2 
[Mean Cq Values] 
Plasma centrifuged 47.1* 37.8* 
Plasma non-centrifuged 46.9* 37.6* 
Serum centrifuged 46.1* 37.2* 
Serum non-centrifuged 47.2* 37.0* 
 529 
 530 
